TGFB1 and acute myeloid leukemia: The decrease of TGFβ1 expression in AML patients is closely related to the poor prognosis of AML patients, which can provide a reference for improving the clinical efficacy of AML patients (Tamai et al., 2017; Chen W. T. et al., 2020).